NCT04568902View on ClinicalTrials.gov

Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2025

Conditions

Breast Neoplasms

Interventions

DRUG

H3B-6545

H3B-6545 oral tablets.

DRUG

Antihistamine

Systemic antihistamine oral drug such as fexofenadine, loratadine and cetirizine.

Trial Locations (2)

Unknown

Eisai Trial Site 2, Chūōku

Eisai Trial Site 1, Kōtoku

All Listed Sponsors

lead

Eisai Co., Ltd.

INDUSTRY

NCT04568902 - Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | Biotech Hunter | Biotech Hunter